Azelastine/budesonide intranasal - Sedor

Drug Profile

Azelastine/budesonide intranasal - Sedor

Alternative Names: Captisol-enabled™ Budesonide + Azelastine nasal spray - Sedor; CDX-313; LGD-313

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CyDex Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class Glucocorticoids; Phthalazines; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Seasonal allergic rhinitis

Most Recent Events

  • 04 Oct 2017 Azelastine/budesonide is still at phase II development stage for Seasonal allergic rhinitis in Canada (Intranasal) (Sedor Pharmaceuticals website, October 2017)
  • 08 Dec 2015 Captisol-enabled™ azelastine/budesonide licensed to RODES Pharmaceuticals in USA
  • 08 Dec 2015 RODES plans a phase I trial for Seasonal allergic rhinitis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top